LIP
MRNA icon

Liontrust Investment Partners’s Moderna MRNA Stock Holding History

Liontrust Investment Partners’s Portfolio MRNA Stock Details MRNA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-53,860
Closed -$1.39M – 213
2025
Q3 		$1.39M Sell
53,860
-77,896
-59% -$2.17M 0.02% 156
2025
Q2 		$3.64M Sell
131,756
-9,583
-7% -$252K 0.05% 135
2025
Q1 		$4.01M Sell
141,339
-8,907
-6% -$316K 0.06% 133
2024
Q4 		$6.25M Buy
150,246
+137,246
+1,056% +$6.56M 0.09% 116
2024
Q3 		$1.54M Hold
13,000
– – 0.02% 156
2024
Q2 		$1.54M Sell
13,000
-85,000
-87% -$10.8M 0.02% 156
2024
Q1 		$10.4M Sell
98,000
-18,000
-16% -$1.81M 0.15% 99
2023
Q4 		$11.5M Buy
116,000
+56,000
+93% +$4.71M 0.17% 94
2023
Q3 		$6.2M Sell
60,000
-14,000
-19% -$1.56M 0.1% 110
2023
Q2 		$8.99M Buy
74,000
+52,000
+236% +$6.94M 0.13% 99
2023
Q1 		$3.38M Buy
22,000
+4,000
+22% +$660K 0.05% 152
2022
Q4 		$3.23M Sell
18,000
-12,000
-40% -$1.96M 0.06% 117
2022
Q3 		$3.55M Buy
+30,000
New +$4.55M 0.06% 158
2021
Q4 		– Sell
-50,000
Closed -$19.2M – 225
2021
Q3 		$19.2M Buy
+50,000
New +$18.4M 0.27% 50

Other funds holding MRNA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
TP
Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Liontrust Investment Partners's MRNA Position: Q4 2025 in Review

Liontrust Investment Partners sold out of Moderna (MRNA) in Q4 2025, closing a stake of 53,860 shares — an estimated $1.39M sold.

Liontrust Investment Partners first reported a position in MRNA in Q3 2021 and held it in 14 quarters. The position peaked at $19.2M in Q3 2021. 673 funds tracked by Wall St. Rank hold MRNA as of Q4 2025.

  • Liontrust Investment Partners reported no remaining Moderna position as of Q4 2025 after selling out during the quarter.
  • Liontrust Investment Partners sold 53,860 Moderna shares in Q4 2025, an estimated $1.39M.
  • Liontrust Investment Partners first reported a position in Moderna in Q3 2021 and held it in 14 quarters.
  • Liontrust Investment Partners's Moderna position peaked at $19.2M in Q3 2021.
  • 673 funds tracked by Wall St. Rank held Moderna as of Q4 2025.

Based on Liontrust Investment Partners's 13F filing for Q4 2025, filed 17 Feb 2026.